Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

24Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Dual specificity phosphatase 6 (DUSP6) is a protein phosphatase that deactivates extracellular-signal-regulated kinase (ERK). Since the ovarian cancer biomarker human epididymis protein 4 (HE4) interacts with the ERK pathway, we sought to determine the relationship between DUSP6 and HE4 and elucidate DUSP6’s role in epithelial ovarian cancer (EOC). Viability assays revealed a significant decrease in cell viability with pharmacological inhibition of DUSP6 using (E/Z)-BCI hydrochloride in ovarian cancer cells treated with carboplatin or paclitaxel, compared to treatment with either agent alone. Quantitative PCR was used to evaluate levels of ERK pathway response genes to BCI in combination with recombinant HE4 (rHE4), carboplatin, and paclitaxel. Expression of EGR1, a promoter of apoptosis, was higher in cells co-treated with BCI and paclitaxel or carboplatin than in cells treated with chemotherapeutic agents alone, while expression of the proto-oncogene c-JUN was decreased with co-treatment. The effect of BCI on the expression of these two genes opposed that of rHE4. Pathway focused quantitative PCR also revealed suppression of ERBB3 in cells co-treated with BCI plus carboplatin or paclitaxel. Finally, expression levels of DUSP6 in EOC tissue were evaluated by immunohistochemistry, revealing significantly increased levels of DUSP6 in serous EOC tissue compared to adjacent normal tissue. A positive correlation between HE4 and DUSP6 levels was determined by Spearman Rank correlation. In conclusion, DUSP6 inhibition sensitizes ovarian cancer cells to chemotherapeutic agents and alters gene expression of ERK response genes, suggesting that DUSP6 could plausibly function as a novel therapeutic target to reduce chemoresistance in EOC.

References Powered by Scopus

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

742Citations
N/AReaders
Get full text

A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy

533Citations
N/AReaders
Get full text

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3

369Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway

29Citations
N/AReaders
Get full text

LncRNA BBOX1-AS1 Aggravates the Development of Ovarian Cancer by Sequestering miR-361-3p to Augment PODXL Expression

24Citations
N/AReaders
Get full text

Adaptive responses as mechanisms of resistance to braf inhibitors in melanoma

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

James, N. E., Beffa, L., Oliver, M. T., Borgstadt, A. D., Emerson, J. B., Chichester, C. O., … Ribeiro, J. R. (2019). Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes. Oncotarget, 10(36), 3315–3327. https://doi.org/10.18632/oncotarget.26915

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

75%

Researcher 2

25%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 8

73%

Medicine and Dentistry 1

9%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Chemistry 1

9%

Save time finding and organizing research with Mendeley

Sign up for free